Hyaluronidase-loaded PLGA microparticles as a new strategy for the treatment of pulmonary fibrosis

Tissue Engineering - Part A

Volumn 21, Issue 1-2, 2015, Pages 246-256

  Da Silva Bitencourt, Claudia ^a,c   Gelfuso, Guilherme Martins ^b   Pereira, Priscilla Aparecida Tartari ^a   De Assis, Patrícia Aparecida ^a   Tefé Silva, Cristiane ^a   Ramos, Simone Gusmão ^a   Arantes, Eliane Candiani ^a   Faccioli, Lúcia Helena ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c Centro Universitário das Faculdades Associadas de Ensino São João da Boa Vista   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; BIOLOGICAL ORGANS; COPOLYMERS; EMULSIFICATION; ENCAPSULATION; ENZYME ACTIVITY; MAMMALS; ORGANIC POLYMERS;

AVERAGE DIAMETER; COLLAGEN DEPOSITION; DELIVERY SYSTEMS; ENCAPSULATION EFFICIENCY; PLGA MICROPARTICLES; POLY(D ,L-LACTIDE-CO-GLYCOLIDE); PULMONARY FIBROSIS; SOLVENT EVAPORATION METHOD;

PEPTIDES;

5' NUCLEOTIDASE; BLEOMYCIN; COLLAGEN; ENDOTOXIN; HYALURONIDASE; INTERLEUKIN 13; KERATINOCYTE DERIVED CHEMOKINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYGLACTIN; STEM CELL ANTIGEN 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; HYALURONOGLUCOSAMINIDASE; LACTIC ACID; MICROSPHERE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ARTICLE; COLLAGEN FIBER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG UPTAKE; ENCAPSULATION; ENZYME ACTIVITY; EVAPORATION; IMMUNOPHENOTYPING; IN VITRO STUDY; INFLAMMATION; LIMULUS LYSATE TEST; LUNG FIBROSIS; LUNG FLUID; LUNG HOMOGENATE; LUNG PARENCHYMA; MICROEMULSION; MICROENCAPSULATION; MONONUCLEAR CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURFACE CHARGE; ZETA POTENTIAL; ANIMAL; BOVINE; C57BL MOUSE; CELL COUNT; CELL LINE; CHEMISTRY; COMPLICATION; CYTOLOGY; CYTOSKELETON; GENETICS; METABOLISM; PARTICLE SIZE; PATHOLOGY; PHAGOCYTE; PULMONARY FIBROSIS; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; STATIC ELECTRICITY;

BOVINAE; MUS;

ANIMALS; CATTLE; CELL COUNT; CELL LINE; COLLAGEN; CYTOSKELETON; HYALURONOGLUCOSAMINIDASE; LACTIC ACID; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; PHAGOCYTES; PNEUMONIA; POLYGLYCOLIC ACID; PULMONARY FIBROSIS; RNA, MESSENGER; SOLUBILITY; STATIC ELECTRICITY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84921359065     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2013.0403     Document Type: Article

References (41)

1. Mouratis, M.A., and Aidinis, V. Modeling pulmonary fi-brosis with bleomycin. Curr Opin Pulm Med 17, 355, 2011.
2. Hardie, W.D., Glasser, S.W., and Hagood, J.S. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 175, 3, 2009.
3. King, T.E., Jr., Pardo, A., and Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949, 2011.
4. Raghu, G., Weycker, D., Edelsberg, J., Bradford, W.Z., and Oster, G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174, 810, 2006.
5. O'Connell, O.J., Kennedy, M.P., and Henry, M.T. Idio-pathic pulmonary fibrosis: treatment update. Adv Ther 28, 986, 2011.
6. Menzel, E.J., and Farr, C. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett 131, 3, 1998.
7. Dunn, A.L., Heavner, J.E., Racz, G., and Day, M. Hya-luronidase: a review of approved formulations, indications and off-label use in chronic pain management. Expert Opin Biol Ther 10, 127, 2010.
8. Kemparaju, K., and Girish, K.S. Snake venom hyaluron-idase: a therapeutic target. Cell Biochem Funct 24, 7, 2006.
9. Hynes, W.L., Dixon, A.R., Walton, S.L., and Aridgides, L.J. The extracellular hyaluronidase gene (hylA) of Streptococcus pyogenes. FEMS Microbiol Lett 184, 109, 2000.
10. Jiang, D., Liang, J., and Noble, P.W. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23, 435, 2007.
11. Bitencourt, C.S., Pereira, P.A., Ramos, S.G., Sampaio, S.V., Arantes, E.C., Aronoff, D.M., and Faccioli, L.H. Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis. Fibrogenesis Tissue Repair 4, 3, 2011.
12. Girish, K.S., and Kemparaju, K. The magic glue hyalur-onan and its eraser hyaluronidase: a biological overview. Life Sci 80, 1921, 2007.
13. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., and Aminabhavi, T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Release 125, 193, 2008.
14. Allen, T.M., and Cullis, P.R. Drug delivery systems: entering the mainstream. Science 303, 1818, 2004.
15. Nicolete, R., Lima Kde, M., Júnior, J.M., Baruffi, M.D., de Medeiros, A.I., Bentley, M.V., Silva, C.L., and Faccioli, L.H. In vitro and in vivo activities of leukotriene B4-loaded biodegradable microspheres. Prostaglandins Other Lipid Mediat 83, 121, 2007.
16. Wischke, C., and Schwendeman, S.P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 364, 298, 2008.
17. Dos Santos, D.F., Bitencourt, C.S., Gelfuso, G.M., Pereira, P.A., de Souza, P.R., Sorgi, C.A., Nicolete, R., and Fac-cioli, L.H. Biodegradable microspheres containing leuko-triene B(4) and cell-free antigens from Histoplasma capsulatum activate murine bone marrow-derived macro-phages. Eur J Pharm Sci 44, 580, 2011.
18. dos Santos, D.F., Nicolete, R., de Souza, P.R., Bitencourt C da, S., dos Santos, R.R., Jr., Bonato, V.L., Silva, C.L., and Faccioli, L.H. Characterization and in vitro activities of cell-free antigens from Histoplasma capsulatum-loaded biodegradable microspheres. Eur J Pharm Sci 38, 548, 2009.
19. Shoyele, S.A. Engineering protein particles for pulmonary drug delivery. Methods Mol Biol 437, 149, 2008.
20. Shoyele, S.A., and Cawthorne, S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 58, 1009, 2006.
21. Chow, A.H., Tong, H.H., Chattopadhyay, P., and Sheku-nov, B.Y. Particle engineering for pulmonary drug delivery. Pharm Res 24, 411, 2007.
22. Bordon, K.C., Perino, M.G., Giglio, J.R., and Arantes, E.C. Isolation, enzymatic characterization and antiedematogenic activity of the first reported rattlesnake hyaluronidase from Crotalus durissus terrificus venom. Biochimie 94, 2740, 2012.
23. Ortiz, L.A., Gambelli, F., McBride, C., Gaupp, D., Baddoo, M., Kaminski, N., and Phinney, D.G. Mesenchymal stem cell engraftment in lung is enhanced in response to bleo-mycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 100, 8407, 2003.
24. Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T.R., Horowitz, J.C., Pennathur, S., Martinez, F.J., and Thannickal, V.J. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 15, 1077, 2009.
25. Padua, A.I., Silva, C.L., Ramos, S.G., Faccioli, L.H., and Martinez, J.A. Influence of a DNA-hsp65 vaccine on bleo-mycin-induced lung injury. J Bras Pneumol 34, 891, 2008.
26. Tabata, Y., and Ikada, Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9, 356, 1988.
27. Champion, J.A., Walker, A., and Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 25, 1815, 2008.
28. Lawrence, T., Willoughby, D.A., and Gilroy, D.W. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2, 787, 2002.
29. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D.J., and Horwitz, E. Minimal criteria for defining multi-potent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315, 2006.
30. Weiss, D.J., Bertoncello, I., Borok, Z., Kim, C., Panoskaltsis-Mortari, A., Reynolds, S., Rojas, M., Stripp, B., Warburton, D., and Prockop, D.J. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 8, 223, 2011.
31. Wang, X., Hisha, H., Taketani, S., Adachi, Y., Li, Q., Cui, W., Cui, Y., Wang, J., Song, C., Mizokami, T., Okazaki, S., Li, Q., Fan, T., Fan, H., Lian, Z., Gershwin, M.E., and Ike-hara, S. Characterization of mesenchymal stem cells isolated from mouse fetal bone marrow. Stem Cells 24, 482, 2006.
32. Obayashi, Y., Yamadori, I., Fujita, J., Yoshinouchi, T., Ueda, N., and Takahara, J. The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 112, 1338, 1997.
33. Kim, S.J., Angel, P., Lafyatis, R., Hattori, K., Kim, K.Y., Sporn, M.B., Karin, M., and Roberts, A.B. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10, 1492, 1990.
34. de Figueiredo-Pontes, L.L., Assis, P.A., Santana-Lemos, B.A., Jácomo, R.H., Lima, A.S., Garcia, A.B., Thomé, C.H., Araújo, A.G., Panepucci, R.A., Zago, M.A., Nagler, A., Falca-o, R.P., and Rego, E.M. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One 6, e26713, 2011.
35. Wang, Q., Wang, Y., Hyde, D.M., Gotwals, P.J., Kote-liansky, V.E., Ryan, S.T., and Giri, S.N. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 54, 805, 1999.
36. Grande, N.R., Pea-o, M.N.D., de Sá, C.M., and Aguas, A.P. Lung fibrosis induced by bleomycin: structural changes and overview of recent advances. Scanning Microsc 12, 487, 1998.
37. Siniscalco, D., Sullo, N., Maione, S., Rossi, F., and D'Agostino, B. Stem cell therapy: the great promise in lung disease. Ther Adv Respir Dis 2, 173, 2008.
38. Moodley, Y., Atienza, D., Manuelpillai, U., Samuel, C.S., Tchongue, J., Ilancheran, S., Boyd, R., and Trounson, A. Human umbilical cord mesenchymal stem cells reduce fi-brosis of bleomycin-induced lung injury. Am J Pathol 175, 303, 2009.
39. Benjamin, D.K., Jr., Miller, W.C., Bayliff, S., Martel, L., Alexander, K.A., and Martin, P.L. Infections diagnosed in the first year after pediatric stem cell transplantation. Pe-diatr Infect Dis J 21, 227, 2002.
40. Engelhard, D., Cordonnier, C., Shaw, P.J., Parkalli, T., Guenther, C., Martino, R., Dekker, A.W., Prentice, H.G., Gustavsson, A., Nurnberger, W., and Ljungman, P. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 117, 444, 2002.
41. Garćia-Castro, J., Trigueros, C., Madrenas, J., Pérez-Simón, J.A., Rodriguez, R., and Menendez, P. Mesenchy-mal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 12, 2552, 2008.